Key session presented at the International Congress of Infectious Diseases (ISID), 17th-20th Nov. 2022, Malaysia.

A single-center real-life study evaluated the clinical and laboratory parameters of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. The study identified high blood eosinophil levels, chronic rhinosinusitis with nasal polyps, and low pre-treatment lung capacity as predictors of omalizumab treatment response.

A new study reported that elevated urine albumin-to-creatinine ratio (uACR) is an independent risk factor for new-onset heart failure (HF) in patients with T2D. The risk of HF increases by 2.21fold when uACR is mildly elevated (3–30 mg/mmol) and when uACR ≥30 mg/mmol, the risk of HF increases by 6.02 fold. The findings may serve as reference for screening and assessing high-risk HF patients in T2D patients.